This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): imiquimod 2.5% or 3.75%, Vyloma (Canada, for HPV)
Description: BioMedTracker has two separate profiles for imiquimod. Please also see Aldara.
Imiquimod is an immune response modifier (IRM). IRMs act by stimulating the body to produce cytokines, naturally occurring proteins used by cells of the immune system to communicate with each other. The cytokines induced by IRMs enhance cell-mediated immunity, a natural process by which the body controls or eliminates virus infected cells and tumor cells.
Meda and Graceway
In May 2010, Meda acquired exclusive European rights to 3.75% imiquimod topical cream from Graceway Pharmaceuticals. In consideration for exclusive European rights for 3.75% imiquimod, Meda will pay Graceway an undisclosed up-front and a single digit royalty on net sales. No milestones payments will be due for 3.75% imiquimod.
Medicis and Graceway
In November 2011, Medicis announced that it was the successful bidder at a bankruptcy auction conducted by Graceway Pharmaceuticals for substantially all of the outstanding U.S. and Canadian pharmaceutical assets of Graceway. The transaction closed in December 2011.
Medicis and Valeant
In September 2012, Valeant and Medicis announced that they entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44.00 per share in cash. The combined company's commercial dermatology operations will operate under the name Medicis, a...See full deal structure in Biomedtracker
Partners: Mylan Inc.
Additional information available to subscribers only: